Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07257484 · ClinicalTrials.gov registry record · Phase 4
Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors
A Phase 4 study, sponsored by Weill Medical College of Cornell University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT07257484 is a Phase 4 study that is actively recruiting participants, run by Weill Medical College of Cornell University. The registered enrollment target is 30 participants.
The verdict
NCT07257484, a Phase 4 study, is actively recruiting participants, sponsored by Weill Medical College of Cornell University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study will explore whether tirzepatide is a practical and acceptable treatment for postmenopausal females with a history of hormone receptor-positive breast cancer and obesity. The investigators aim to understand whether participants are willing and able to take this medication once weekly for 6 months and whether it may help improve weight and overall health. There will be monthly check-ins to monitor progress and safety. At the beginning and end of the study, participants will undergo body composition assessments, blood tests and a stool sample will be collected, and surveys will be completed.
Interventions
- DRUG Tirzepatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-06-08 |
| Est. Completion | 2028-02-25 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07257484
The ClinicalTrials.gov registry entry for NCT07257484 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tirzepatide is the first listed.
NCT07257484 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07257484 about?
NCT07257484 is a clinical study titled "Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors". This study will explore whether tirzepatide is a practical and acceptable treatment for postmenopausal females with a history of hormone receptor-positive breast cancer and obesity. The investigators aim to understand whether participants are willing and able to take this medication once weekly for ...
What is the current status of trial NCT07257484?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2026-06-08. Estimated completion is 2028-02-25.
What interventions are being tested in trial NCT07257484?
The interventions under investigation include: Tirzepatide (DRUG).
Who is sponsoring clinical trial NCT07257484?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.